Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models

Summary & key facts

This paper reviews lab and human studies about how classic psychedelics like LSD and psilocybin, and non-classic ones like ketamine and MDMA, change the brain's ability to rewire itself. The authors say these drugs seem to make the brain more open to change, which could explain why a single or a few doses can lead to quick and lasting shifts in mood or behaviour. Most of the strong evidence comes from animal experiments, and moving those findings to people is hard because brain imaging tools are limited, though new methods are starting to help.

Key facts:

• What the authors did: they looked at many animal and human studies to see how classic psychedelics and non-classic psychedelics affect neuroplasticity, which is the brain's ability to change and adapt.
• Main finding: psychedelics often produce fast and lasting effects after just one or a few doses, and those effects are thought to come from boosting the brain's capacity to change.
• Classic versus non-classic: classic psychedelics named in the paper include LSD and psilocybin. Non-classic examples the paper discusses include ketamine and MDMA.
• Animal results: studies in animals suggest psychedelics can make the nervous system more sensitive to the environment, a change the authors call meta-plasticity, and can re-open developmental-style windows when the brain is more able to form long-term structural changes, which they call hyper-plasticity.
• Limits in humans: translating animal findings to people is difficult because current human brain imaging methods do not yet capture these plasticity changes well.
• Future directions: the paper highlights new tools that could help study plasticity in people, such as improved PET brain scans, non-invasive brain stimulation, and combining different measurement methods.
• Why this matters: understanding how psychedelics change brain wiring could guide new treatments for mood and other psychiatric problems, but the review cautions that more human-focused research is needed before strong clinical claims can be made.

Abstract

Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment target for neuropsychiatric conditions. Psychedelics, a burgeoning category of drugs, are increasingly prominent in psychiatric research, prompting inquiries into their mechanisms of action. Distinguishing themselves from traditional medications, psychedelics demonstrate rapid and enduring therapeutic effects after a single or few administrations, believed to stem from their neuroplasticity-enhancing properties. This review examines how classic psychedelics (e.g., LSD, psilocybin, N,N-DMT) and non-classic psychedelics (e.g., ketamine, MDMA) influence neuroplasticity. Drawing from preclinical and clinical studies, we explore the molecular, structural, and functional changes triggered by these agents. Animal studies suggest psychedelics induce heightened sensitivity of the nervous system to environmental stimuli (meta-plasticity), re-opening developmental windows for long-term structural changes (hyper-plasticity), with implications for mood and behavior. Translating these findings to humans faces challenges due to limitations in current imaging techniques. Nonetheless, promising new directions for human research are emerging, including the employment of novel positron-emission tomography (PET) radioligands, non-invasive brain stimulation methods, and multimodal approaches. By elucidating the interplay between psychedelics and neuroplasticity, this review informs the development of targeted interventions for neuropsychiatric disorders and advances understanding of psychedelics' therapeutic potential.

Topics

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies

Categories

Clinical Psychology Psychology Social Sciences

Tags

Neuroplasticity Neuroscience Psychology

Substances

Ketamine LSD MDMA Psilocybin

Conditions & symptoms

Anxiety Depression PTSD Anxiety or worry Feeling disconnected from others Sadness or low mood